Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 30 citing articles:

Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study
Mingyue Cai, Wensou Huang, Wei Liang, et al.
Liver International (2024) Vol. 44, Iss. 4, pp. 920-930
Closed Access | Times Cited: 9
Cost-Effectiveness Analysis of Camrelizumab Plus Rivoceranib Versus Sorafenib as a First-Line Therapy for Unresectable Hepatocellular Carcinoma in the Chinese Health Care System
W.J. Lang, Lian Deng, Bei Huang, et al.
Clinical Drug Investigation (2024) Vol. 44, Iss. 3, pp. 149-162
Closed Access | Times Cited: 7
Effect of transcatheter arterial chemoembolization combined with lenvatinib plus anti–PD-1 antibodies in patients with unresectable hepatocellular carcinoma: A treatment with Chinese characteristics
Jiayi Wu, Junyi Wu, Shuqun Li, et al.
BioScience Trends (2024) Vol. 18, Iss. 1, pp. 42-48
Open Access | Times Cited: 4
Comparison of tumor response and outcomes of patients with hepatocellular carcinoma after multimodal treatment including immune checkpoint inhibitors – a systematic review and meta-analysis
Zaiba Shafik Dawood, Zachary J. Brown, Laura Alaimo, et al.
HPB (2024) Vol. 26, Iss. 5, pp. 618-629
Closed Access | Times Cited: 4
Clinical efficacy of lenvatinib, trans-arterial chemoembolization, and PD-1/L1 inhibitors in advanced hepatocellular carcinoma: a systematic review and network meta-analysis
YiFeng Liang, L M Gan, DeJin Zeng, et al.
Clinical & Translational Oncology (2024) Vol. 26, Iss. 10, pp. 2652-2664
Closed Access | Times Cited: 3
Hepatitis B Virus Reactivation in Patients With HBV-Related Advanced Hepatocellular Carcinoma Undergoing Lenvatinib and Camrelizumab Treatment
Sheng Bi, Dong Wang, Jingjing Wang
Cancer Control (2025) Vol. 32
Open Access
Lenvatinib plus immunotherapy versus lenvatinib monotherapy in lenvatinib-insensitive patients with unresectable hepatocellular carcinoma: a retrospective study
Zeyu Yu, Bin Leng, Ran You, et al.
Investigational New Drugs (2025)
Open Access
Treatment of intermediate-to-advanced unresectable hepatocellular carcinoma is shifting toward a multidisciplinary strategy that includes multiple modalities as needed
Ken Sato
World Journal of Gastroenterology (2025) Vol. 31, Iss. 10
Closed Access
PD-1 inhibitors improve the efficacy of tyrosine kinase inhibitors combined with transcatheter arterial chemoembolization in advanced hepatocellular carcinoma: a meta-analysis and trial sequential analysis
Jiahui Yu, Yong Li, Yuting Yang, et al.
Scandinavian Journal of Gastroenterology (2025), pp. 1-13
Closed Access
Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study
Shuqun Li, Junyi Wu, Jiayi Wu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 8
Efficacy and safety of transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors in the treatment of unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Junning Liu, Wei Song, Linfeng Yang, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 15, pp. 14451-14461
Closed Access | Times Cited: 7
Efficacy and safety of transarterial chemoembolization combined with targeted therapy and immunotherapy versus with targeted monotherapy in unresectable hepatocellular carcinoma: A systematic review and meta-analysis
Jingwen Feng, Yi Zhao, Lin Zhai, et al.
Medicine (2024) Vol. 103, Iss. 18, pp. e38037-e38037
Open Access | Times Cited: 2
Transarterial chemoembolization combined donafenib with/without PD-1 for unresectable HCC in a multicenter retrospective study
Hao Li, Jiacheng Wang, Guokun Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study
Guosheng Yuan, Wenli Li, Mengya Zang, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Lenvatinib Combined with the PD-1 Inhibitor Camrelizumab in the Treatment of Primary Liver Cancer Caused Hemorrhagic Exfoliative Gastritis
Hong Chen, Zihua Wang, Chunhua Wang
Case Reports in Oncology (2024) Vol. 17, Iss. 1, pp. 543-548
Open Access | Times Cited: 1
Efficacy and safety of TACE combined with tyrosine kinase inhibitors and camrelizumab for unresectable hepatocellular carcinoma: A systematic review and meta‑analysis
Jiahui Yu, Yan Duan, Wei Song, et al.
Oncology Letters (2024) Vol. 28, Iss. 2
Open Access | Times Cited: 1
Combined transarterial chemoembolization and tislelizumab for patients with unresectable hepatocellular carcinoma
Bin-Bin Tan, Ying Fu, Minghua Shao, et al.
World Journal of Gastrointestinal Surgery (2024) Vol. 16, Iss. 9, pp. 2829-2841
Closed Access | Times Cited: 1
Neutrophil-to-lymphocyte ratio predicts therapy outcomes of transarterial chemoembolization combined with tyrosine kinase inhibitors plus programmed cell death ligand 1 antibody for unresectable hepatocellular carcinoma
Xin Zheng, Kun Qian
Anti-Cancer Drugs (2022)
Closed Access | Times Cited: 7
Targeting metabolic reprogramming promotes the efficacy of transarterial chemoembolization in the rabbit VX2 liver tumor model
Yi Luo, Yong Yang, Meize Ye, et al.
Oncology Letters (2024) Vol. 27, Iss. 3
Open Access
Transarterial chemoembolization combined with atezolizumab plus bevacizumab conversion therapy for intermediate-stage hepatocellular carcinoma: a case report and literature review
Haidong Ai, Ting Gong, Yongbiao Ma, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Comparison of the efficacy and safety of immunotherapy combined with lenvatinib at different time points in unresectable hepatocellular carcinoma: a single-center retrospective study
Zeyu Yu, Bin Leng, Ran You, et al.
Research Square (Research Square) (2024)
Open Access
Predictive Value of Peripheral Blood Eosinophil Count on the Efficacy of Treatment with Camrelizumab in Combination with Lenvatinib in Patients with Advanced Hepatitis B-Associated Hepatocellular Carcinoma
Xiaoxiao Chen, Haonan Liu, Di Pan, et al.
Technology in Cancer Research & Treatment (2024) Vol. 23
Open Access
Camrelizumab Combined with Transcatheter Arterial Chemoembolization for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
Li Liu, Wenyu He, Jiaoping Liu
Clinics and Research in Hepatology and Gastroenterology (2024), pp. 102465-102465
Closed Access
Prognostic value of platelet-to-lymphocyte ratio in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization and tyrosine kinase inhibitors plus immune checkpoints inhibitors
Yiwan Guo, Wenlong Wu, Bo Sun, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
The combination of ALPPS, interventional hepatoma therapy, targeted therapy, and immunotherapy: A novel conversion therapy model for unresectable HCC
Chen Zhu, Haiyang Hu, Xingyu Chen, et al.
Research Square (Research Square) (2024)
Closed Access
Page 1 - Next Page

Scroll to top